Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice

Postgraduate Medicine

Volumn 121, Issue 1, 2009, Pages 40-45

  Bohannon, Nancy ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Comparison; DPP4 inhibition; Gliptin; Pharmacotherapy; Review; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; VILDAGLIPTIN; GLUCAGON;

ADD ON THERAPY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DEGRADATION; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; FAST FOOD; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RELEASE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; TIMED DRUG RELEASE; TREATMENT DURATION; CLASSIFICATION; DRUG EFFECT; METABOLISM; MULTICENTER STUDY; PANCREAS ISLET; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON; GLUCOSE; HUMANS; ISLETS OF LANGERHANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 60549107240     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.01.1953     Document Type: Article

References (31)

1. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest. 1984;74(4):1318-1328. (Pubitemid 15206828)
2. Tsalikian E, Dunphy TW, Bohannon NV, et al. The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal. Diabetes. 1977;26(4):314-321. (Pubitemid 8086533)
3. Bohannon NV, Karam JH, Lorenzi M, Gerich JE, Matin SB, Forsham PH. Plasma glucagon suppression by phenformin in man. Diabetologia. 1977;13(5):503-508. (Pubitemid 8206737)
4. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492-498. (Pubitemid 16035703)
5. Kelley D, Mokan M, Veneman T. Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus. Metabolism. 1994;43(12):1549-1557. (Pubitemid 24382707)
6. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-3723. (Pubitemid 32755966)
7. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992;326(1):22-29.
8. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med. 1970;283(3):109-115.
9. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1- (7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999;140(11):5356-5363.
10. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol. 1996;271(3 pt 1):E458-E464. (Pubitemid 126757539)
11. Ahrén B L-OMJP. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinology Metab. 2004;89(5):2078-2084. (Pubitemid 38619835)
12. Drugstore.com Online Pharmacy. www.drugstore.com. Accessed December 14, 2008.
13. Braceras R, et al. Vildagliptin is as effective as TZDs in metformin failures: results of GALIANT - a primary care diabetes study. In: Abstract book from the 44th Annual Meeting of the European Association for the Study of Diabetes. P 914. September 7-11, 2008; Rome, Italy.
14. Boschmann M, et al. Dipeptidyl-peptidase 4 inhibition augments postprandial lipid mobilisation and oxidation in type 2 diabetic patients. In: Abstract book from the 44th Annual Meeting of the European Association for the Study of Diabetes. P 916. September 7-11, 2008; Rome, Italy.
15. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564-2571.
16. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin 035 Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733-745. (Pubitemid 47261855)
17. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin 020 Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638-2643. (Pubitemid 44912191)
18. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin 019 Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(10): 1556-1568. (Pubitemid 44841980)
19. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams- Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979-1987. (Pubitemid 47219404)
20. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890-895. (Pubitemid 46556583)
21. Ahrén B, et al. Vildagliptin improves á-cell glucose sensing in patients with type 2 diabetes. In: Abstract book from the 44th Annual Meeting of the European Association for the Study of Diabetes. OP 75. September 7-11, 2008; Rome, Italy.
22. Thuren T, et al. Vildagliptin is safe and well tolerated in patients with mild or moderate renal impairment. In: Abstract book from the 44th Annual Meeting of the European Association for the Study of Diabetes. OP 74. September 7-11, 2008; Rome, Italy.
23. Goodman M, et al. Improved glycaemic control with vildagliptin 100 rng administered cither as a morning or evening dose as add-on therapy to metformin in type 2 diabetes mellitus. Presented at: 44th Annual Meeting of the European Association for the Study of Diabetes. P 913. September 7-11, 2008; Rome, Italy.
24. Kothny W, et al. Cardiovascular safely profile of vildagliptin, a new DPP-4 inhibitor for the treatment of type 2 diabetes. In: Abstract book from the 44th Annual Meeting of the European Association for the Study of Diabetes. P915. September 7-11, 2008; Rome, Italy.
25. DeFronzo R, Fleck P, Wilson C, Mekki Q. Alogliptin monotherapy improves glycemic control in patients with type 2 diabetes. Abstract 446 P. Diabetes. 2008;57(suppl 1):A133.
26. Fleck P, Christopher R, Covington P, Wilson C, Mekki Q. Efficacy and safety of alogliptin monotherapy in patients with type 2 diabetes. Abstract 479 P. Diabetes. 2008;57(suppl 1):A143.
27. Pratley R, Kipnes M, Fleck P, Wilson C, Mekki Q. Alogliptin added to sulfonylurea therapy in patients with type 2 diabetes reduces HbA1c without increasing hypoglycemia. Abstract 445 P. Diabetes. 2008;57(suppl 1):A133.
28. Pratley R, Reusch J, Fleck P, Wilson C, Mekki Q. Efficacy and safety of alogliptin added to pioglitazone therapy in patients with type 2 diabetes. Abstract 478 P. Diabetes. 2008;57(suppl 1):A143.
29. 1c, without increasing weight gain or hypoglycemia. Abstract 444 P. Diabetes. 2008;57(suppl 1):A132.
30. Fleck P, Mekki O, Kipnes M, Wilson C, Pratley R. Efficacy and safety of alogliptin and glyburide combination therapy in patients with type 2 diabetes. Presented at: 44th Annual Meeting of the European Association for the Study of Diabetes. P 76. September 7-11, 2008; Rome, Italy.
31. Nauck M, Ellis G, Fleck P, Wilson C, Mekki Q. Efficacy and safety of alogliptin added to metformin therapy in patients with type 2 diabetes. Abstract 477 P. Diabetes. 2008;57(suppl 1):A142.